Rise and shine, everyone, another busy day is on the way. Our first clue is that the short person has left summer behind and is now stationed in front of a laptop for remote learning. And since the official mascot has successfully completed his morning calisthenics, we are free to get cracking. Toward that end, we are firing up the coffee kettle and examining our to-do list. Meanwhile, here are a few items of interest. We hope your journey today is productive and, as always, do keep in touch. We appreciate the feedback and juicy tips. …

A large, Phase 3 study testing a Covid-19 vaccine being developed by AstraZeneca (AZN) and the University of Oxford at dozens of sites across the U.S. has been put on hold due to a suspected serious adverse reaction in a participant in the United Kingdom, STAT reports. AstraZeneca initiated the study hold. The nature of the adverse reaction and when it happened were not immediately known, but the participant is expected to recover.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy